KURAA little biotech bragging rights
Kura Oncology just dropped updated clinical data for its darlifarnib plus adagrasib combo in KRAS G12C-mutated solid tumors, and the headline is simple: the tumors shrank in 77% of response-evaluable patients. Not bad for a space where “promising” is often doing Olympic-level heavy lifting.
Why investors are perked up
This isn’t just a clean number on a slide deck. Kura says the activity showed up even in heavily pretreated patients and people who had already seen KRAS inhibitors before. That matters because in biotech, the hard part is rarely getting a drug to work in a pristine lab setup — it’s getting it to work after the patient has already been through the wringer.
The safety box also matters
The company also flagged a strong safety profile, which is the other half of the biotech survival kit. You can have all the efficacy in the world, but if the side effects turn the whole thing into a medical soap opera, the market usually looks elsewhere.
Big picture
For Kura, this kind of readout can keep the story alive and give investors another reason to watch the pipeline instead of just the chart. Early clinical wins don’t guarantee a home run, but in biotech they’re often the thing standing between “speculative” and “worth keeping on the radar.”